Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. US20140199301 - Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)

Office United States of America
Application Number 13808295
Application Date 07.07.2010
Publication Number 20140199301
Publication Date 17.07.2014
Grant Number 09193792
Grant Date 24.11.2015
Publication Kind B2
IPC
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/2863
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2863against receptors for growth factors, growth regulators
C07K 2317/622
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
60characterized by non-natural combinations of immunoglobulin fragments
62comprising only variable region components
622Single chain antibody (scFv)
C07K 2317/73
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
A61K 31/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 38/1866
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
1858Platelet-derived growth factor [PDGF]
1866Vascular endothelial growth factor [VEGF]
Applicants Berrin Erda{hacek over (g)}
TUBITAK
Bertan Koray Balcio{hacek over (g)}lu
Aylin Ozdemir Bahadir
Aydin Bahar
Kemal Baysal
Müge Serhatli
Omer Kaçar
Türker Kiliç
Emel Akgün
Abdulkadir Özkan
Inventors Berrin Erda{hacek over (g)}
Bertan Koray Balcio{hacek over (g)}lu
Aylin Ozdemir Bahadir
Aydin Bahar
Kemal Baysal
Müge Serhatli
Omer Kaçar
Türker Kiliç
Emel Akgün
Abdulkadir Özkan
Agents Brinks Gilson & Lione
Title
(EN) Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (VEGFR—2/KDR)
Abstract
(EN)

Phage displayed recombinant antibody library was developed and the library was screened against VEGFR-2. After screening and ELISA experiments two recombinant antibodies showing binding properties to VEGFR-2 was obtained. The difference of the two recombinant antibodies to the recombinant antibodies already developed was demonstrated by DNA sequence analysis. The inhibition effect of the two recombinant antibodies on endothelial cell proliferation was demonstrated with cell assays. Thus these recombinant antibodies might be used as VEGF related angiogenesis inhibitors.